Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes

Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou, Tao Jiang


Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).